Boshoff currently serves as chief oncology officer and is credited with delivering 24 approved new medicines and biosimilars during his 11-year tenure at the company. Boshoff has also worked as Pfizer’s head of development in Japan and as chief development officer for oncology and rare disease.
“Dr. Boshoff is the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organization with a more focused strategy,” Pfizer CEO Albert Bourla said in the company’s statement. He credited Boshoff with running one of the company’s most productive divisions and said he has a “compelling vision” for future research and development.
As the new head of research, Boshoff will be tasked with revving up a pipeline that some investors have found disappointing. Pfizer achieved an astonishing success developing a COVID-19 vaccine in a matter of months in 2020 and raked in billions of dollars during the pandemic, pushing its shares above $59 in late 2021. Since then, the stock has more than halved, however.
The activist investor Starboard Value argues that Pfizer executives wasted their COVID-19 windfall on bad acquisitions while neglecting innovation. Last month, Starboard pushed the company’s board “to hold management accountable for earning appropriate returns on R&D and M&A moving forward.” READ MORE
By Kristin Jensen
Source: biopharmadive.com
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have said they expect to close before year-end—just received a major vote of confidence from antitrust officials overseas.
With EuroAPI’s restructuring plan underway, the Sanofi spinoff has pulled a new CEO from within its ranks to guide the company’s next chapter. Drug ingredients specialist EuroAPI on Monday said it had accepted the resignations of Ludwig de Mot as CEO and Viviane Monges as chair of the manufacturer’s board.
During an investor update Thursday, Lonza unveiled its “One Lonza” restructuring strategy, under which the company will reorganize its CDMO business, reshape its operating model, work to “elevate” manufacturing and engineering and expand its production footprint.
